Ben Yerxa

Ben Yerxa has a diverse work experience in the biotechnology and pharmaceutical industries. Ben currently serves as the CEO of Opus Genetics and has held this position since July 2022. Additionally, they serve as a Board Member at Clearside Biomedical, Inc., NACUITY PHARMACEUTICALS, INC., Sharefish.org, and the North Carolina Biotechnology Center.

In the past, Ben Yerxa was a Board Member at SparingVision from December 2017 to July 2022. Ben also served as the CEO of Foundation Fighting Blindness from October 2017 to July 2022, and as the CEO of RD Fund from October 2018 to June 2022.

Furthermore, Ben Yerxa has experience as a Board Member at Atsena Therapeutics from May 2020 to July 2021. Ben also had a leadership role at Envisia Therapeutics, where they served as President from March 2015 to October 2017 and as Chief Scientific Officer from November 2013 to February 2015.

Ben Yerxa pursued their education in the field of Chemistry, starting with a Bachelor of Arts degree in Chemistry from UC San Diego. Ben completed this program between 1984 and 1988. Afterwards, they chose to specialize further and obtained a Doctorate in Organic Chemistry from UC Irvine, which they completed between 1989 and 1993.